Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus (Q44183696)

30 November 2017

title

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus (English)

1 reference

30 November 2017

main subject

Staphylococcus aureus

1 reference

2

Barry N Kreiswirth

1 reference

30 November 2017

1

Donald E Low

1 reference

30 November 2017

4

Barbara M Willey

1 reference

30 November 2017

Karl Weiss

3

1 reference

30 November 2017

publication date

1 September 2002

1 reference

30 November 2017

number of pages

3

1 reference

International Journal of Antimicrobial Agents

inferred from page(s)

published in

1 reference

30 November 2017

volume

20

1 reference

30 November 2017

issue

3

1 reference

30 November 2017

page(s)

220-222

1 reference

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900132-2

7 January 2021

10.1016/S0924-8579(02)00132-2

Identifiers

DOI

1 reference

30 November 2017

1 reference